Veracyte Stock Buy Hold or Sell Recommendation
| VCYT Stock | USD 31.82 0.02 0.06% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Veracyte is 'Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Veracyte given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Veracyte, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Veracyte Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide. Note, we conduct extensive research on individual companies such as Veracyte and provide practical buy, sell, or hold advice based on investors' constraints. Veracyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Veracyte |
Execute Veracyte Buy or Sell Advice
The Veracyte recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Veracyte. Macroaxis does not own or have any residual interests in Veracyte or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Veracyte's advice using the current market data and latest reported fundamentals.
Time Horizon
3 Months |
Risk Tolerance
I am an educated risk taker |
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Veracyte Trading Alerts and Improvement Suggestions
| Veracyte generated a negative expected return over the last 90 days | |
| Veracyte has high historical volatility and very poor performance | |
| Veracyte is unlikely to experience financial distress in the next 2 years | |
| Veracyte has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from investors.com: Stocks Showing Improving Market Leadership Veracyte Earns 81 RS Rating |
Veracyte Returns Distribution Density
The distribution of Veracyte's historical returns is an attempt to chart the uncertainty of Veracyte's future price movements. The chart of the probability distribution of Veracyte daily returns describes the distribution of returns around its average expected value. We use Veracyte price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Veracyte returns is essential to provide solid investment advice for Veracyte.
| Mean Return | -0.4 |
| Value At Risk | -5.12 |
| Potential Upside | 4.18 |
| Standard Deviation | 3.42 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Veracyte historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Veracyte Stock Institutional Investors
The Veracyte's institutional investors refer to entities that pool money to purchase Veracyte's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | |||
| Geode Capital Management, Llc | 2024-12-31 | 1.8 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 1.2 M | |
| Gw&k Investment Management, Llc | 2024-12-31 | 1.2 M | |
| Nuveen Asset Management, Llc | 2024-12-31 | 1.2 M | |
| Driehaus Capital Management Llc | 2024-12-31 | 1.2 M | |
| Northern Trust Corp | 2024-12-31 | 1.1 M | |
| Marshall Wace Asset Management Ltd | 2024-12-31 | 956.6 K | |
| Bamco Inc | 2024-12-31 | 879.8 K | |
| Fisher Asset Management, Llc | 2024-12-31 | 845.7 K | |
| Vanguard Group Inc | 2024-12-31 | 8.2 M | |
| Blackrock Inc | 2024-12-31 | 7.5 M |
Veracyte Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 1.1M | (1.5M) | (3.0M) | (1.7M) | (5.9M) | (5.6M) | |
| Change In Cash | 190.0M | (176.0M) | (19.0M) | 62.3M | 23.3M | 18.6M | |
| Free Cash Flow | (12.5M) | (37.0M) | (1.0M) | 34.3M | 63.8M | 67.0M | |
| Depreciation | 7.9M | 19.6M | 25.9M | 27.2M | 23.5M | 24.6M | |
| Other Non Cash Items | 2.7M | 3.9M | 7.7M | 66.3M | 12.8M | 6.9M | |
| Capital Expenditures | 2.8M | 5.4M | 8.5M | 10.0M | 11.3M | 11.9M | |
| Net Income | (34.9M) | (75.6M) | (36.6M) | (74.4M) | 24.1M | 25.3M | |
| End Period Cash Flow | 350.0M | 173.9M | 155.0M | 217.3M | 240.6M | 128.5M | |
| Change Receivables | (6.2M) | 955K | (8.6M) | (4.5M) | (4.0M) | (4.2M) | |
| Net Borrowings | (292K) | (25.2M) | (100K) | (1.3M) | (1.2M) | (1.1M) | |
| Change To Netincome | 9.8M | 15.6M | 26.4M | 27.6M | 31.8M | 33.3M | |
| Investments | (1M) | 3M | (20.8M) | (8.8M) | (56.3M) | (53.5M) |
Veracyte Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Veracyte or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Veracyte's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Veracyte stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.33 | |
β | Beta against Dow Jones | 1.22 | |
σ | Overall volatility | 3.40 | |
Ir | Information ratio | -0.1 |
Veracyte Volatility Alert
Veracyte exhibits very low volatility with skewness of -0.93 and kurtosis of 4.02. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Veracyte's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Veracyte's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Veracyte Fundamentals Vs Peers
Comparing Veracyte's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Veracyte's direct or indirect competition across all of the common fundamentals between Veracyte and the related equities. This way, we can detect undervalued stocks with similar characteristics as Veracyte or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Veracyte's fundamental indicators could also be used in its relative valuation, which is a method of valuing Veracyte by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Veracyte to competition |
| Fundamentals | Veracyte | Peer Average |
| Return On Equity | 0.0218 | -0.31 |
| Return On Asset | 0.0139 | -0.14 |
| Profit Margin | 0.05 % | (1.27) % |
| Operating Margin | 0.07 % | (5.51) % |
| Current Valuation | 2.24 B | 16.62 B |
| Shares Outstanding | 77.94 M | 571.82 M |
| Shares Owned By Insiders | 0.84 % | 10.09 % |
| Shares Owned By Institutions | 99.16 % | 39.21 % |
| Number Of Shares Shorted | 3.13 M | 4.71 M |
| Price To Earning | (10.61) X | 28.72 X |
| Price To Book | 2.11 X | 9.51 X |
| Price To Sales | 5.56 X | 11.42 X |
| Revenue | 445.76 M | 9.43 B |
| Gross Profit | 309.7 M | 27.38 B |
| EBITDA | 49.2 M | 3.9 B |
| Net Income | 24.14 M | 570.98 M |
| Cash And Equivalents | 170.11 M | 2.7 B |
| Cash Per Share | 2.37 X | 5.01 X |
| Total Debt | 50.74 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 4.09 X | 2.16 X |
| Book Value Per Share | 15.12 X | 1.93 K |
| Cash Flow From Operations | 75.1 M | 971.22 M |
| Short Ratio | 3.63 X | 4.00 X |
| Earnings Per Share | 0.31 X | 3.12 X |
| Target Price | 44.5 | |
| Number Of Employees | 824 | 18.84 K |
| Beta | 1.8 | -0.15 |
| Market Capitalization | 2.48 B | 19.03 B |
| Total Asset | 1.3 B | 29.47 B |
| Retained Earnings | (443.98 M) | 9.33 B |
| Working Capital | 293.63 M | 1.48 B |
| Current Asset | 47.91 M | 9.34 B |
Note: Acquisition by Marc Stapley of 90601 shares of Veracyte subject to Rule 16b-3 [view details]
Veracyte Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Veracyte . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Veracyte Buy or Sell Advice
When is the right time to buy or sell Veracyte? Buying financial instruments such as Veracyte Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Veracyte in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marijuana Thematic Idea Now
Marijuana
Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States. The Marijuana theme has 22 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marijuana Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.